Fdg pet with contrast-enhanced CT: A critical imaging tool for laryngeal carcinoma

Radiographics

Volumn 30, Issue 5, 2010, Pages 1353-1372

  Chu, Mae Mae A Y ^a   Kositwattanarerk, Arpakorn ^a   Lee, David J ^a   Makkar, Jasnit S ^a   Genden, Eric M ^a   Kao, Johnny ^a   Packer, Stuart H ^a   Som, Peter M ^a   Kostakoglu, Lale ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; IMAGE ENHANCEMENT; IMAGE SUBTRACTION; LARYNX TUMOR; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY;

FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; LARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77957730830     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.305095764     Document Type: Article

References (70)

1. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER cancer statistics review, 1975-2006. Bethesda, Md: National Cancer Institute. http://seer.cancer.gov/csr/1975_2006/. Based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed November 1, 2009.
2. Nikolaou AC, Markou CD, Petridis DG, Daniilidis IC. Second primary neoplasms in patients with laryngeal carcinoma. Laryngoscope 2000;110(1): 58-64.
3. Curtin HD. The larynx. In: Som PM, Curtin HD, eds. Head and neck imaging. 4th ed. St Louis, Mo: Mosby, 2003; 1595-1699.
4. Becker M, Burkhardt K, Dulguerov P, Allal A. Imaging of the larynx and hypopharynx. Eur J Radiol 2008;66(3):460-479.
5. Zbären P, Becker M, Läng H. Pretherapeutic staging of hypopharyngeal carcinoma: clinical findings, computed tomography, and magnetic resonance imaging compared with histopathologic evaluation. Arch Otolaryngol Head Neck Surg 1997;123(9): 908-913.
6. Harnsberger HR. The larynx and hypopharynx. In: Gay SM, ed. Handbook of head and neck imaging. 2nd ed. St Louis, Mo: Mosby, 1994; 224-259.
7. Zbären P, Becker M, Läng H. Pretherapeutic staging of laryngeal carcinoma: clinical findings, computed tomography, and magnetic resonance imaging compared with histopathology. Cancer 1996;77(7): 1263-1273.
8. Sigg MB, Steinert H, Grätz K, Hugenin P, Stoeckli S, Eyrich GK. Staging of head and neck tumors: [18F]fluorodeoxyglucose positron emission tomography compared with physical examination and conventional imaging modalities. J Oral Maxillofac Surg 2003;61(9):1022-1029.
9. Zimmer LA, Branstetter BF, Nayak JV, Johnson JT. Current use of 18F-fluorodeoxyglucose positron emission tomography and combined positron emission tomography and computed tomography in squamous cell carcinoma of the head and neck. Laryngoscope 2005;115(11):2029-2034.
10. Schwartz DL, Rajendran J, Yueh B, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130(12):1361-1367.
11. Minn H, Lapela M, Klemi PJ, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997;38 (12):1907-1911.
12. Wong RJ, Lin DT, Schöder H, et al. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20(20):4199-4208.
13. American Joint Committee on Cancer. Cancer staging manual. 6th ed. New York, NY: Springer-Verlag, 2002.
14. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008;83(4):489-501.
15. Som PM, Curtin HD, Mancuso AA. An imaging-based classification for the cervical nodes designed as an adjunct to recent clinically based nodal classifications. Arch Otolaryngol Head Neck Surg 1999; 125(4):388-396.
16. Harnsberger HR. Squamous cell carcinoma: nodal staging. In: Gay SM, ed. Handbook of head and neck imaging. 2nd ed. St Louis, Mo: Mosby, 1994; 283-298.
17. Puri SK, Fan CY, Hanna E. Significance of extracapsular lymph node metastases in patients with head and neck squamous cell carcinoma. Curr Opin Otolaryngol Head Neck Surg 2003;11(2):119-123.
18. Yousem DM, Hatabu H, Hurst RW, et al. Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 1995;195(3):715-720.
19. Hannah A, Scott AM, Tochon-Danguy H, et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 2002;236(2): 208-217.
20. Braams JW, Pruim J, Freling NJ, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36(2):211-216.
21. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36(10):1747-1757.
22. McGuirt WF, Williams DW 3rd, Keyes JW Jr, et al. A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope 1995;105(4 pt 1):373-375.
23. Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999;125(12):1322-1328.
24. Yamazaki Y, Saitoh M, Notani K, et al. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 2008;22(3):177-184.
25. Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007;48(suppl 1):58S-67S.
26. Schöder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34(3):180-197.
27. Jeong HS, Baek CH, Son YI, et al. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck 2007;29(3):203-210.
28. Roh JL, Yeo NK, Kim JS, et al. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma. Oral Oncol 2007;43(9):887-893.
29. Schwartz DL, Ford E, Rajendran J, et al. FDG-PET/ CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;61(1):129-136.
30. Mukherji SK, Bradford CR. Controversies: is there a role for positron-emission tomographic CT in the initial staging of head and neck squamous cell carcinoma? AJNR Am J Neuroradiol 2006;27(2): 243-245.
31. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomog-raphy to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100(10): 712-720.
32. Hafidh MA, Lacy PD, Hughes JP, Duffy G, Timon CV. Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas. Eur Arch Otorhinolaryngol 2006;263(9):853-859.
33. Murakami R, Uozumi H, Hirai T, et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2007;68(2):377-382.
34. Gourin CG, Watts TL, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. Laryngoscope 2008;118(4):671-675.
35. Senft A, de Bree R, Hoekstra OS, et al. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol 2008;87 (2):221-229.
36. Schmid DT, Stoeckli SJ, Bandhauer F, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 2003;113(5):888-891.
37. Schwartz DL, Rajendran J, Yueh B, et al. Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg 2003;129(11):1173-1178.
38. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 2001;23(12):1056-1060.
39. Gourin CG, Watts T, Williams HT, Patel VS, Bilodeau PA, Coleman TA. Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. Laryngoscope 2009;119(4):703-706.
40. Wax MK, Myers LL, Gabalski EC, Husain S, Gona JM, Nabi H. Positron emission tomography in the evaluation of synchronous lung lesions in patients with untreated head and neck cancer. Arch Otolaryngol Head Neck Surg 2002;128(6):703-707.
41. Kim SY, Roh JL, Yeo NK, et al. Combined 18F-fluorodeoxyglucose-positron emission tomography and computed tomography as a primary screening method for detecting second primary cancers and distant metastases in patients with head and neck cancer. Ann Oncol 2007;18(10):1698-1703.
42. Strobel K, Haerle SK, Stoeckli SJ, et al. Head and neck squamous cell carcinoma (HNSCC): detection of synchronous primaries with (18)F-FDG-PET/ CT. Eur J Nucl Med Mol Imaging 2009;36(6): 919-927.
43. Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007;117(7):1173-1179.
44. Bold B, Piao Y, Murata Y, Kishino M, Shibuya H. Usefulness of PET/CT for detecting a second primary cancer after treatment for squamous cell carcinoma of the head and neck. Clin Nucl Med 2008; 33(12):831-833.
45. Leemans CR, Tiwari R, Nauta JJP, van der Waal I, Snow GB. Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor. Cancer 1994;73(1):187-190.
46. Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck 2001;23(11):933-941.
47. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ. T4 laryngeal carcinoma: radiotherapy alone with surgery reserved for salvage. Int J Radiat Oncol Biol Phys 1998;40(3):549-552.
48. Spector JG, Sessions DG, Chao KS, et al. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation. Head Neck 1999;21(8):707-717.
49. Terhaard CH, Hordijk GJ, van den Broek P, et al. T3 laryngeal cancer: a retrospective study of the Dutch Head and Neck Oncology Cooperative Group-study design and general results. Clin Otolaryngol Allied Sci 1992;17(5):393-402.
50. Moose BD, Greven KM. Definitive radiation management for carcinoma of the glottic larynx. Otolaryngol Clin North Am 1997;30(1):131-143.
51. Medini E, Medini I, Lee CK, Gapany M, Levitt SH. Curative radiotherapy for stage II-III squamous cell carcinoma of the glottic larynx. Am J Clin Oncol 1998;21(3):302-305.
52. Kitagawa Y, Nishizawa S, Sano K, et al. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003;44(2):198-206.
53. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/ CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006;65(5):1315-1322.
54. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33(3):210-222.
55. Brouwer J, Hooft L, Hoekstra OS, et al. Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. Head Neck 2008;30(7):889-897.
56. Martin RC, Fulham M, Shannon KF, et al. Accuracy of positron emission tomography in the evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer. Head Neck 2009;31 (2):244-250.
57. Gordin A, Daitzchman M, Doweck I, et al. Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management. Laryngoscope 2006;116 (2):273-278.
58. Fakhry N, Lussato D, Jacob T, Giorgi R, Giovanni A, Zanaret M. Comparison between PET and PET/ CT in recurrent head and neck cancer and clinical implications. Eur Arch Otorhinolaryngol 2007;264 (5):531-538.
59. Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000;110(3 pt 2 suppl 93): 1-18.
60. Horiuchi C, Taguchi T, Yoshida T, et al. Early assessment of clinical response to concurrent chemoradiotherapy in head and neck carcinoma using fluoro-2-deoxy-d-glucose positron emission tomography. Auris Nasus Larynx 2008;35(1):103-108.
61. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck 2005;27(3):175-181.
62. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 2000;110(9):1493-1497.
63. Ong SC, Schöder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008;49 (4):532-540.
64. Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 2005;115(4):645-650.
65. Perlow A, Bui C, Shreve P, Sundgren PC, Teknos TN, Mukherji SK. High incidence of chest malignancy detected by FDG PET in patients suspected of recurrent squamous cell carcinoma of the upper aerodigestive tract. J Comput Assist Tomogr 2004; 28(5):704-709.
66. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 2009;50(suppl 1):74S-88S.
67. Minn H, Paul R, Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 1988;29(9):1521-1525.
68. Brun E, Kjellén E, Tennvall J, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24(2):127-135.
69. Fukui MB, Blodgett TM, Snyderman CH, et al. Combined PET-CT in the head and neck: 2. Diagnostic uses and pitfalls of oncologic imaging. RadioGraphics 2005;25(4):913-930.
70. Stokkel MP, Bongers V, Hordijk GJ, van Rijk PP. FDG positron emission tomography in head and neck cancer: pitfall or pathology? Clin Nucl Med 1999;24(12):950-954.